Office of Technology Transfer – University of Michigan

Device to Deploy Diagnostic or Therapeutic Agent with or without Biopsy

Technology #3939


Approximately 2% to 5% of patients undergoing biopsies in the United States suffer from serious bleeding complications due to the diagnostic procedure. The risk of bleeding from a biopsy procedure is the leading risk associated with biopsies and is the reason physicians refrain from conducting these procedures on high risk patients even though diagnostic information from a biopsy would be valuable in treating the patient. Attempts to mitigate this problem using coagulopathy have yielded some benefit, however in cases where coagulopathy causes excessive strain on organs a more effective solution is needed. There is a need for a biopsy device to control for bleeding at the site of tissue sampling without causing excessive strain on the body.


Researchers at the University of Michigan have developed a biopsy device to address the current limitations for renal biopsies. The device includes a collection needle, which collects tissue, as well as a mechanism for concomitantly releasing a hemostatic agent into the tissue void upon needle retraction. The technology utilizes a design that incorporates standard methods for performing a biopsy and includes a method for delivering local coagulating treatment. The device can also be used for rapid and local deployment of a therapeutic agent within the body, acting as a local drug delivery tool. The researchers have designed a new device that addresses the major problem with biopsies and maintains the current method of biopsy procedures.

Applications and Advantages


  • Kidney biopsy


  • Reduce cost of care with more accurate diagnoses through safer kidney biopsies
  • Minimizes bleeding due to biopsy, reduces complications during diagnosis
  • Reduces risk during diagnosis operations